[Pubmed] Treatment strategy for myasthenia gravis with GAD65-IgG associated neurological disorders: A case report
Posté : 07 sept. 2025 12:00
J Neuroimmunol. 2025 Aug 31;409:578741. doi: 10.1016/j.jneuroim.2025.578741. Online ahead of print.
ABSTRACT
We present a clinically instructive case of a 50-year-old woman with acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (MG) who subsequently developed glutamic acid decarboxylase 65 (GAD65) antibody-associated neurological disorders alongside a type B2 thymoma. This rare coexistence highlights the profound immune dysregulation induced by thymomas, wherein loss of self-tolerance emergence multiple concurrent autoimmune phenomena. The patient's favorable response to multimodal immunotherapy-including efgartigimod, high-dose corticosteroids, and rituximab-underscores the therapeutic imperative for early, targeted immunomodulation in such complex neuroimmunological syndromes. As no standardized treatment currently exists for MG with GAD65-IgG-associated neurological disorders, this case provides critical clinical insights into both the diagnostic and therapeutic approach for this complex disease.
PMID:40915254 | DOI:10.1016/j.jneuroim.2025.578741
Source: https://pubmed.ncbi.nlm.nih.gov/4091525 ... t9+e462414